Miromatrix Medical Inc. Nabs $23 Million for Decellularizing Tech

Decellularization technology developer MiroMatrix Medical raised $23 million in a new round of equity financing, according to an SEC filing posted last week.

MiroMatrix develops and utilizes a proprietary technology to remove cells, or decellularize, organs and tissue.

Currently, MiroMatrix has 510(k) clearance for its MiroMesh biological mesh used during hernia repair procedures and as a general wound treatment, and plans to submit additional applications for other indications, according to its website.

Help employers find you! Check out all the jobs and post your resume.

Back to news